0000899243-21-032571.txt : 20210811
0000899243-21-032571.hdr.sgml : 20210811
20210811182656
ACCESSION NUMBER: 0000899243-21-032571
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210809
FILED AS OF DATE: 20210811
DATE AS OF CHANGE: 20210811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hack Andrew A. F.
CENTRAL INDEX KEY: 0001657434
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34207
FILM NUMBER: 211164953
MAIL ADDRESS:
STREET 1: 300 THIRD STREET, FIRST FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DYNAVAX TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0001029142
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330728374
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 POWELL STREET
STREET 2: SUITE 900
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5108485100
MAIL ADDRESS:
STREET 1: 2100 POWELL STREET
STREET 2: SUITE 900
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-09
0
0001029142
DYNAVAX TECHNOLOGIES CORP
DVAX
0001657434
Hack Andrew A. F.
C/O BAIN CAPITAL LIFE SCIENCES INVESTORS
200 CLARENDON STREET
BOSTON
MA
02116
1
0
0
0
Common Stock
2021-08-09
4
C
0
2249000
0.00
A
10774000
I
See footnotes
Common Stock
2021-08-09
4
S
0
2250000
10.80
D
8524000
I
See footnotes
Series B Convertible Preferred Stock
0.00
2021-08-09
4
C
0
2249
0.00
D
2019-08-12
Common Stock
2249000
1891
I
See footnotes
Represents securities held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").
Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Each share of Series B Convertible Preferred Stock is convertible, at the option of the holder, into 1,000 shares of the Issuer's common stock and has no expiration date. The Series B Convertible Preferred Stock is not convertible if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of the Issuer's common stock then issued and outstanding immediately after giving effect to the conversion. On August 9, 2021, the Bain Capital Life Sciences Entities converted an aggregate of 2,249 shares of Series B Convertible Preferred Stock into an aggregate of 2,249,000 shares of the Issuer's common stock.
/s/ Andrew Hack
2021-08-11